Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined...
Patent
1997-10-29
2000-07-18
Witz, Jean C.
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
424572, A61K 3556
Patent
active
060904135
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD OF THE INVENTION
The field of the present invention is organ allograft survival. More specifically, the field of the present invention is prolongation of organ allograft survival. Organ allograft survival is prolonged by down-regulating Th1 activity in an organism receiving an organ allograft.
BACKGROUND OF THE INVENTION
The development of novel immunosuppressive drugs has caused a dramatic increase in the short term survival of organ transplants in recent years. The use of such drugs, however, is associated with side effects such as opportunistic infections, tumors and ultimately, chronic rejection.
The recent description of two subsets of T helper cells (Th), with different cytokine secretion profiles and activities, may provide a new paradigm for immunoregulation of organ allograft rejection (Mosmann et al., Inmunol. Today, 8:223, 1987). The two Th cell subsets, designated Th1 and Th2, can be characterized on the basis of their respective cytokine production profiles. Th1 cells produce and secrete interferon-gamma (IFN-.gamma.), lymphotoxin (LT) and interleukin-2 (IL-2). On the other hand, Th2 cells produce and secrete interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6) and interleukin-10 (IL-10).
Acute organ allograft rejection may result from responses associated with the pro-inflammatory cytokines IL-2, IFN-.gamma., and TNF-.alpha., derived from Th1 cells. Down-regulation of Th1 activity, therefore, may be a useful immunomodulatory therapy. It is also well known that infection by certain parasitic organisms can modulate the balance between Th1 and Th2 activity. By way of example, Sher and coworkers have demonstrated that a depression of Th1-type responses can be achieved by helminth infection (Sher et al., J. Immunol., 147:2713, 1991). Helminth infection can also result in up-regulation or stimulation of Th activity. Nematode induced up-regulation can encompass stimulation of IgE (and IgG1 in mice or IgG4 in humans), mast cell hyperplasia and eosinophilia in all species, including humans.
It is well known that the immune modulation associated with helminth infection is unrelated to the worm antigens per se. For example, greater than 80 percent of the IgE generated during Nipostrongylus brasiliensis (N. brasiliensis) infection was found not to be directed to N. brasiliensis (Jarrett et al., Clin. Exp. Immunol., 24:326, 1976).
Such induced up-regulation may be due to the cross-regulatory actions of the Th1/Th2 system. The Th1 and Th2 subsets have been found to be cross-regulatory with respect to differentiation and activity. By way of example, cytokines produced by Th2 cells (e.g., IL-4 and IL-10) inhibit Th1 cell growth and cytokine production and ablate the effects of Th1 cytokines (e.g., IFN-.gamma.) on their targets, while IFN-.gamma. inhibits Th2 function (Powrie et al., Immunol. Today, 14:270, 1993).
The concept of resistance or susceptibility being related to Th1/Th2 balance has also been suggested in a variety of other models, including AIDS, and even successful pregnancy. The finding of pro-inflammatory cytokines IL-2, IFN-.gamma., TNF-.alpha. and IL-6 in rejecting kidney allografts lends support to the hypothesis that Th1-type T cells orchestrate the immune response, which culminates in rejection. It likely that a Th1/Th2 balance is established within the graft which changes over time, differs among individuals, and is dependent on the treatment administered but that the cellular mechanisms behind graft rejection, such as infiltration by macrophages and CTL, are consistent with the activities of Th1 cells.
BRIEF SUMMARY OF THE INVENTION
In one aspect, the present invention provides a process of prolonging organ allograft survival in an organism comprising down-regulating Th1 activity in the organism.
In a preferred embodiment, the down-regulation of Th1 activity is accomplished by infecting the organism with an effective Th2 up-regulating amount of a nematode.
In another preferred embodiment, the down-regulation of Th1 activity is accomplished by administer
REFERENCES:
N.E. Street et al., Faseb Journal for Experimental Biology, "Functional Diversity of T Lymphocytes Due to Secretion of Different Cytokine Patterns", vol. 5, No. 2, pp. 174, Feb. 1991.
A. Sher et al., Journal of Immunology, "Production of Il-10 by CD4+ Lymphocytes correlates with Down-Regulation of Th1 Cytokine Synthesis in Helminth Infection", vol. 147, No. 8, pp. 2713-2716, Oct. 15, 1991.
Bradley et al., Mayo Clin Proc 53:332-335, 1978.
Krenger et al., Transplantation, 58(11):1251-1257, Dec. 15, 1994.
Barriga, Immunology, 34:167-173, 1978.
Caulada-Benedetti et al., Journal of Immunology, 146(5):1655-1660, Mar. 1, 1991.
Kupiec-Weglinski et al., Journal of Immunology, 151(9):5053-5061, Nov. 1, 1993.
Grzych et al., Journal of Immunology, 146(4):1322-1327, 1991.
Else et al., Parasite Immunology 15(10): 595-600 (1993).
Jenkins et al., Transactions of the Royal Society of Tropical Medicine and Hygeine 88(3): 269-273 (1994).
Mazumder et al., Indian Journal of Gastroenterology 11(3): 117-120 (1992).
Hogaboam et al., Journal of Lipid Mediators 4(2): 211-224 (1991).
Lee et al., Immunology 47: 227-232 (1982).
Ishikawa et al., Parasite Immunology 16: 181-186 (1994).
Mayberry et al., Journal of Parasitology 79(6): 962-963 (1993).
Allen et al., International Archives of Allergy and Immunology 109(1): 3-10 (1996).
Else et al., Immunology 72: 508-513 (1991).
Fahey, Basic Concepts of Organ Procurement, Perfusion and Preservation for Transplantation, Academic Press, New York, 1992.
The Merck Manual of Diagnosis and Therapy, Merck & Co., Rahway, NJ, 1992.
Allen et al., Parasite Immunology 20: 241-247 (1998).
Lee Timothy D.
McAlister Vivian G.
LandOfFree
Process of prolonging organ allograft survival does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process of prolonging organ allograft survival, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process of prolonging organ allograft survival will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2033956